1. Bond GS. Effect of various agents on the blood flow through the coronary arteries and veins. J Exp Med. 1910; 12:575–85.
Article
2. Marsh N, Marsh A. A short history of nitroglycerine and nitric ox-ide in pharmacology and physiology. Clin Exp Pharmacol Physiol. 2000; 27:313–9.
Article
3. Chen Z, Foster MW, Zhang J. . An essential role for mitochon-drial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2005; 102:12159–64.
Article
4. Bonini MG, Stadler K, Silva SO. . Constitutive nitric oxide syn-thase activation is a significant route for nitroglycerin-mediated vasodilation. Proc Natl Acad Sci U S A. 2008; 105:8569–74.
Article
5. Sydow K, Daiber A, Oelze M. . Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitro-glycerin tolerance and cross-tolerance. J Clin Invest. 2004; 113:482–9.
Article
6. Kleschyov AL, Oelze M, Daiber A. . Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circ Res. 2003; 93:e104–12.
Article
7. Millar TM, Stevens CR, Benjamin N. . Xanthine oxidor-eductase catalyses the reduction of nitrates and nitrite to nitric ox-ide under hypoxic conditions. FEBS Lett. 1998; 427:225–8.
Article
8. Hill KE, Hunt RW Jr, Jones R. . Metabolism of nitroglycerin by smooth muscle cells: involvement of glutathione and glutathione S-transferase. Biochem Pharmacol. 1992; 43:561–6.
9. Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, Caldwell RW. Role of L-arginine in the vascular actions and development of tol-erance to nitroglycerin. Br J Pharmacol. 2000; 130:211–8.
Article
10. Schwarz M, Katz SD, Demopoulos L. . Enhancement of endo-thelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure. Circulation. 1994; 89:1609–14.
Article
11. Forster C, Main JS, Armstrong PW. Endothelium modulation of the effects of nitroglycerin on blood vessels from dogs with pacing-induced heart failure. Br J Pharmacol. 1990; 101:109–14.
Article
12. Gruhn N, Aldershvile J, Boesgaard S. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats. Eur J Pharmacol. 2001; 416:245–9.
Article
13. Gruhn N, Boesgaard S, Andersen C, Aldershvile J. Nitroglycerin tolerance: different mechanisms in vascular segments with or with-out intact endothelial function. J Cardiovasc Pharmacol. 2002; 40:201–9.
Article
14. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 1984; 91:564–79.
Article
15. Rohen JW, LÜtjen-drecoll E, FlÜgel C. . Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma. Exp Eye Res. 1993; 56:683–92.
16. Wiederholt M, Dörschner N, Groth J. Effect of diuretics, channel modulators, and signal interceptors on contractility of the tra-becular meshwork. Ophthalmologica. 1997; 211:153–60.
Article
17. Wiederholt M, Stumpff F. Civan MM, editor. The trabecular meshwork and aqueous humor reabsorption. Current topics in membranes. The eye's aqueous Humor: from secretion to glaucoma. vol. 45. 1998. San Diego: Academic Press;p. 163–202.
18. Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of tra-becular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci. 1994; 35:2515–20.
19. Behar-Cohen FF, Goureau O, D’Hermies F, Courtois Y. Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye. Invest Ophthalmol Vis Sci. 1996; 37:1711–5.
20. Mosmann T. Rapid colorimetric assay for cellular growth and sur-vival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65((1-2)):55–63.
Article
21. Freimoser FM, Jakob CA, Aebi M, Tuor U. The MTT [3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is a fast and reliable method for colorimetric determination of fungal cell densities. Appl Environ Microbio. 1999; 65:3727–9.
Article
22. Green LC, Wagner DA, Glogowski J. . Analysis of Nitrate, Nitrite and [15N]nitrate in biologic fluids. Analytical Biochem. 1982; 126:131–8.
23. Stamler JS, Jaraki O, Osborne J. . Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A. 1992; 89:7674–7.
Article
24. Schneider AJ, Teule GJ, Groeneveld AB. . The immediate ef-fect of nitroglycerin on total body blood volume distribution in patients with congestive heart failure: A noninvasive study. Eur Heart J. 1987; 8:1119–25.
Article
25. Laslett LJ, Baker L. Sublingual nitroglycerin administered by spray versus tablet: Comparative timing of hemodynamic effects. Cardiology. 1990; 77:303–10.
Article
26. Bauer JA, Fung HL. Arterial versus venous metabolism of nitro-glycerin to nitric oxide: A possible explanation of organic nitrate venoselectivity. J Cardiovasc Pharmacol. 1996; 28:371–4.
Article
27. Dinerman JL, Lawson DL, Mehta JL. Interactions between nitro-glycerin and endothelium in vascular smooth muscle relaxation. Am J Physiol. 1991; 260((3 Pt 2)):H698–701.
Article
28. Bonini MG, Stadler K, Silva SO. . Constitutive nitric oxide synthase activation is a significant route for nitroglycerinmediated Vasodilation. Proc Natl Acad Sci U S A. 2008; 105:8569–74.
Article
29. Mao M, Sudhahar V, Ansenberger-Fricano K. . Nitroglycerin drives endothelial nitric oxide synthase activation via the phospha-tidylinositol 3-kinase/protein kinase B pathway. Free Radic Biol Med. 2012; 52:427–35.
Article
30. Bouloumié A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase 1 expression in en-dothelial cells. Cardiovasc Res. 1999; 41:773–80.
31. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1. Circ Res. 1998; 83:832–40.
32. Laursen JB, Boesgaard S, Poulsen HE, Aldershvile J. Nitrate toler-ance impairs nitric oxide-mediated vasodilation in vivo. Cardiovasc Res. 1996; 31:814–9.
33. Gori T, Parker JD. Nitrate tolerance: A unifying hypothesis. Circulation. 2002; 106:2510–13.